A SIMPLER, SHARPER RECKITT CAGNY 19th February 2026 CAUTIONARY NOTE CONCERNING FORWARD –LOOKING STATEMENTS This presentation and any other information discussed at the presentation (collectively, the "presentation") has been prepared by Reckitt Benckiser Group plc (the "Company") solely for your information. The opinions presented herein are based on general information gathered at the time of writing and are subject to change without notice. Information in this presentation sourced from third parties has b ...

Summary of Reckitt's Focus on Emerging Markets Presentation Company Overview - **Company**: Reckitt - **Focus**: Emerging Markets - **Key Personnel**: Chris Licht (CEO), Nitish Kapoor (President of Emerging Markets), Ryan Daley (Chief Category Growth Officer), Shannon Eisenhardt (CFO) Industry Insights - **Emerging Markets**: Largest geographic area for Reckitt, with significant growth opportunities - **Market Dynamics**: Some emerging markets have already reached advanced market status, while others are still developing Core Points and Arguments 1. **Growth Potential**: Reckitt has seen steady growth in emerging markets, transitioning from mid-single digit growth to high single digit growth over the last decade, with a recent surge to almost 14% growth in the last nine months [11][22][25] 2. **Brand Strength**: Reckitt has established strong, trusted brands in emerging markets, such as Dettol, Harpic, and Durex, which are leaders in their respective categories [14][15][21] 3. **Market Penetration**: The company has increased its market penetration significantly, with Dettol being used over a billion times a year and Harpic growing from GBP 500,000 in revenue in India 27 years ago to an expected GBP 250 million this year [14][17] 4. **Consumer Trends**: Rising incomes and new consumption habits in emerging markets are driving demand for Reckitt's products, with emerging markets expected to contribute 50% of world GDP by 2030 [27][29] 5. **Category Development**: Reckitt is focusing on both mature and nascent categories, with plans to expand into self-care and intimate wellness products, which are gaining traction in these markets [30][54] Additional Important Insights 1. **Local Expertise**: Reckitt's leadership in emerging markets has an average tenure of 21 years, providing deep local knowledge and continuity [9][10] 2. **Distribution Reach**: Products were available in over 10 million stores last year, with 125 million online orders shipped, indicating strong distribution capabilities [18] 3. **Innovation Pipeline**: Reckitt has a robust innovation pipeline ready to be deployed in emerging markets, allowing for quick adaptation to consumer needs [25][32] 4. **Social Impact**: The company is actively involved in societal change, such as improving hygiene practices in India, which has led to a significant increase in household penetration for Harpic [44][47] 5. **Healthcare Partnerships**: Reckitt is engaging with healthcare professionals and policymakers to drive awareness and education about its products, particularly in addressing antibiotic overuse [57][61] Conclusion Reckitt is well-positioned to capitalize on the growth opportunities in emerging markets through its strong brand portfolio, local expertise, and innovative strategies. The company aims to sustain high single-digit growth by leveraging rising incomes and evolving consumer habits while also contributing positively to societal health and well-being.

Trade Policy Impact - The United States has implemented new tariffs, with a 10% baseline tariff on most imports and up to 145% on Chinese goods, significantly affecting global trade dynamics [1] - The elimination of the "de minimis" exemption for shipments under $800 impacts low-cost Chinese e-commerce platforms like Temu and Shein [1] - China has responded by suspending exports of critical minerals, escalating the trade conflict and increasing uncertainty in global markets [1] Economic Consequences - Previous tariffs from 2018 to 2020 resulted in over $80 billion in additional costs for American businesses and consumers, raising concerns about price increases and margin compression across industries [2] - The reintroduction of tariffs in 2025 has raised alarms in the corporate sector, particularly regarding the implementation timeline and potential retaliatory measures from trade partners like China [2] Pharmaceutical Sector - The U.S. government is preparing to impose tariffs on select pharmaceutical imports from countries like China and India, raising concerns about increased costs and supply chain disruptions [3] - Pharmaceutical companies, reliant on international manufacturing, are particularly vulnerable to trade disruptions, leading to a cautious sentiment in the industry [3] Medical Device Sector - The medical device sector is identified as a strong investment opportunity, driven by technological advancements, demographic trends, and increasing demand for healthcare solutions [4] - The global medical devices market was valued at $518.46 billion in 2023 and is projected to grow to over $886.80 billion by 2032, with a CAGR of 6.3% [5] Investment Opportunities - Amid tariff uncertainties, investors are focusing on undervalued stocks with strong balance sheets and resilient performance, particularly in the medical device sector [6] - Promising undervalued stocks for 2025 include Cencora, Inc. (COR), Hims & Hers Health (HIMS), and Prestige Consumer (PBH) [6] Cencora, Inc. - Cencora is a major pharmaceutical services company with a diverse portfolio, including biologics and complex injectables [7] - The company has launched Accelerate Pharmacy Solutions to optimize operations for healthcare customers and has acquired Retina Consultants of America to enhance its specialty leadership [8] - Cencora's stock trades at a P/S ratio of 0.17, lower than the Medical Services market's 0.40, with an expected 11.6% growth in 2025 earnings [9] Hims & Hers Health - Hims & Hers Health offers subscription-based telehealth services and aims to simplify healthcare through a digital-first platform [10] - The company has a P/S ratio of 2.47, discounted compared to the industry's 4.03, with a projected 58% growth in 2025 earnings [11] Prestige Consumer - Prestige Consumer provides over-the-counter healthcare products and has a strong presence across various retail channels [12] - The gastrointestinal product category is a significant growth driver, representing nearly one-fifth of North American sales [13] - The stock trades at a P/S ratio of 3.43, lower than the industry's 5.32, with a recent earnings surprise of 5.17% [16]

Core Insights - Prestige Consumer Healthcare (PBH) is focused on brand building and portfolio expansion through strategic acquisitions, which is expected to drive growth in upcoming quarters [1][5] - The company has experienced a share price increase of 19.3% over the past year, outperforming the industry and S&P 500 [1] Company Overview - PBH has a market capitalization of $4.17 billion and reported an earnings surprise of 5.17% in the last quarter [2] - The earnings yield for PBH stands at 5.4%, significantly higher than the industry's 0.3% [2] Growth Drivers - The strength of PBH's diversified portfolio, which includes well-recognized consumer brands, has contributed to sales growth and long-term profitability, with core brands generating nearly 58.6% of total revenues in fiscal 2024 [3] - The gastrointestinal (GI) product category is a significant contributor, accounting for nearly 20% of North American sales, with brands like Dramamine, Fleet, and Gaviscon leading the category [4] - The company is also seeing growth in the e-commerce channel, reflecting a long-term trend towards online purchases [4] Strategic Acquisitions - PBH has expanded its brand portfolio through both organic growth and acquisitions, including the purchase of TheraTears and other over-the-counter brands from Akorn Operating Company LLC, as well as Hydralyte from Hydration Pharmaceuticals Trust [5] Financial Concerns - As of the end of the fiscal third quarter, PBH had a long-term debt of $996 million and cash and cash equivalents of $51 million, with a debt-to-capital ratio of 35.8% [7] - The company generated approximately 14.8% of its fiscal 2024 revenues from international business, making it susceptible to currency fluctuations [9] Earnings Estimates - The Zacks Consensus Estimate for PBH's fiscal 2025 earnings per share has increased by 0.4% to $4.52, with revenue estimates at $1.13 billion, reflecting a 0.5% increase from the previous year [10]